Vicore Pharma Holding AB (publ) (STO:VICO)
Sweden flag Sweden · Delayed Price · Currency is SEK
8.69
-0.18 (-2.03%)
Aug 4, 2025, 10:58 AM CET

Vicore Pharma Holding AB Company Description

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden.

The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension.

It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis.

It has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF.

The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.

Vicore Pharma Holding AB (publ)
CountrySweden
Founded2000
IndustryBiotechnology
SectorHealthcare
Employees29
CEOAhmed Mousa

Contact Details

Address:
Kornhamnstorg 53
Stockholm, 111 27
Sweden
Phone46 3 17 88 05 60
Websitevicorepharma.com

Stock Details

Ticker SymbolVICO
ExchangeNasdaq Stockholm
Fiscal YearJanuary - December
Reporting CurrencySEK
ISIN NumberSE0007577895
SIC Code2836

Key Executives

NamePosition
Ahmed S. Mousa J.D.Chief Executive Officer
Hans Jeppsson Ph.D.Chief Financial Officer
Mikael NygårdChief Operating Officer
Dr. Johan Raud Ph.D.Chief Scientific Officer
Prof. Bertil Lindmark M.D., Ph.D.Chief Medical Officer
Helen BarkerVice President and Head of CMC
Lene EskildsenHead of Quality Assurance
Anne-Katrine CohrtHead of Clinical Operations
Jonathan LangleyHead of Global Medical Affairs
Jimmie HofmanVice President of Business Development